Alto Neuroscience Class Action Lawsuit: Important Deadline Approaching for Investors

Strategic Insights -

Purchasers of common stock in Alto Neuroscience, Inc. who bought the stock as part of its initial public offering (IPO) on February 2, 2024, or between February 2, 2024, and October 22, 2024, may be entitled to compensation due to allegedly false and misleading statements made by the company. The lawsuit claims that Alto Neuroscience misrepresented the effectiveness of its medication, ALTO-100, in treating major depressive disorder, leading to damages for investors.

Key Takeaways:

  • Alto Neuroscience, Inc. (NYSE: ANRO) is the subject of a class action lawsuit alleging false and misleading statements regarding the effectiveness of its medication, ALTO-100.
  • Investors who purchased common stock in Alto Neuroscience as part of its IPO on February 2, 2024, or between February 2, 2024, and October 22, 2024, may be eligible for compensation.
  • The lead plaintiff deadline is September 19, 2025.
  • The lawsuit claims that Alto Neuroscience's offering documents and public statements were false and/or misleading regarding the clinical, regulatory, and commercial prospects of ALTO-100.
  • The Rosen Law Firm represents investors in this case and offers a contingency fee arrangement.

Statistics:

  • Number of investors potentially affected: Unknown
  • Amount recovered for investors in 2019: $438 million
  • Lawdragon recognition: Laurence Rosen, founding partner, named as a Titan of Plaintiffs' Bar in 2020
  • ISS Securities Class Action Services ranking: Rosen Law Firm ranked No. 1 in securities class action settlements in 2017

Sources:

  • Newsfile Corp. - September 9, 2025 press release
  • https://www.linkedin.com/company/the-rosen-law-firm (Rosen Law Firm Facebook page)
  • https://twitter.com/rosen_firm (Rosen Law Firm Twitter page)
  • https://www.facebook.com/rosenlawfirm (Rosen Law Firm Facebook page)
  • https://www.newsfilecorp.com/release/265742 (Original press release link)